Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Battle Over Plan B In Virginia Focusing On Minors, Colleges

This article was originally published in The Tan Sheet

Executive Summary

Two bills referred to the Virginia Senate limiting availability of Barr's emergency contraceptive Plan B (levonorgestrel .75 mg) could predict similar legislative action in the future

You may also be interested in...

Plan B Switch Decision Deadline Postponed To May

An FDA decision on the Rx-to-OTC switch of emergency contraceptive Plan B (levonorgestrel .75 mg) has been pushed back from February 20 to May 20

House Representatives Worried OTC Plan B May Increase Adolescent STD Risk

Political pressure could affect the pending FDA decision on Barr Labs' application for over-the-counter status for emergency contraceptive Plan B (levonorgestrel)

Plan B Behind-The-Counter Status Discouraged By Panel Members

Barr Labs' Plan B (levonorgestrel) emergency contraceptive was recommended for over-the-counter in a 23-4 vote by the Nonprescription Drugs and Reproductive Health Drugs Advisory Committees at a joint meeting Dec. 16 in Gaithersburg, Md. The joint panel rejected behind-the-counter status for the product





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts